Welcome to BioSeeker Group!

Currently Druggable in Melanoma: A Drug Target Competitive Analysis

Additional Information

Published Date Oct 14, 2008
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 268
PDF Fact Sheet View Fact Sheet for the report Currently Druggable in Melanoma: A Drug Target Competitive Analysis in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$1,950.00

Quick Overview

This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of melanoma drugs.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Currently Druggable in Melanoma: A Drug Target Competitive Analysis.

    To find out more about Currently Druggable in Melanoma: A Drug Target Competitive Analysis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Currently Druggable in Melanoma: A Drug Target Competitive Analysis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This report aims to analyze the current and future potential of melanoma pipeline by examining key fundamentals across the entire pipeline of drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landscape within the pharmaceutical industry; compound type, therapy area and target type.

This report is written for you to identify your competition and understand which targeting strategies are at work within melanoma drug development. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own drug development and who are developing sequels to successful drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversely it may reveal unexpected competition for you.

Drug targets are the critical link between drugs and their role in the treatment of medical disorders. BioSeeker has surveyed the melanoma field and identified 118 drug targets belonging to 124 drugs. This report, Currently Druggable in Melanoma: A Drug Target Competitive Analysis is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of melanoma drugs.

In the report, BioSeeker reports on 94 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 124 melanoma drugs. The highest degree of distinctiveness among the cancer drugs is achieved by sorting each of them according to drug target mix, compound type and R&D approach. At the same time we are also identifying peer groups of drugs, that is, drugs we consider suitable for head-to-head comparison during drug development.

To fuel the scientific and competitive thinking, BioSeeker opens the gate into the presence and relevance of protein-protein interactions between identified targets of melanoma drugs. No less than 207 target-target interactions were recognized among and between 85 of the 118 included melanoma drug targets.

Why You Should Own Your Own Copy of this Report:

  • 268+ pages, with more than 50 different tables and figures. Includes more than 1,000 active links to drug target related resources on the Internet
  • A 124 melanoma drugs analysis, under development by 95 investigators
  • 118 unique, in-depth, drug target validating profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other melanoma drug targets, pursued cancer indications, drugs under development, presence in the Cancer Genome Project etc.
  • A unique drug target combination breakdown of melanoma drugs into R&D approaches
  • Unique drug-protein target interactome- and protein-protein interactome of drug targets analysis
  • Pathway profiling of melanoma drug targets
  • Compound strategies based on sub-cellular localization of drug targets
  • Expression levels of identified drug targets in malignant melanoma tissue
  • Structure based drug design in melanoma
  • Pin-point which competitor drugs’ clinical out-come may have bearing on your own drug development
  • Who are working on sequels to blockbuster drugs?
  • Locate white-spots in the competitive landscape, giving you little or no competition
  • In all, this report is a serious reference for any professional interested in the development of oncology drug targets and the selection/validation of targeting strategies.

1 Executive Summary

2 About Cancer Highlights

3 Methodologies

4 4.1 List of Figures
4.2 List of Tables

5 How to Use this Report

6 Compound Strategies based on Sub-Cellular Localization of Melanoma Drug Targets

7 The Cancer Genome Project and Melanoma Targets
7.1 Melanoma Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer

8 Expression Levels of Identified Drug Targets in Melanoma Tissue

9 Pathway Analysis of Melanoma Drugs

10 Target-Target Interactions among Identified Melanoma Targets

11 Structure-based Drug Design in Melanoma is Stimulated by Available Structure Data on Biological Targets

12 Drug Target Profiles of Melanoma Drugs
12.1.1 Auxiliary Transport Protein Activity Targets
12.1.2 Carboxy-Lyase Activity Targets
12.1.3 Catalytic Activity Targets
12.1.4 Cell Adhesion Molecule Activity Targets
12.1.5 Chaperone Activity Targets
12.1.6 Cofactor Binding Targets
12.1.7 Cytokine Activity Targets
12.1.8 DNA Binding Targets
12.1.9 DNA Repair Protein Targets
12.1.10 DNA Topoisomerase Activity Targets
12.1.11 DNA-Directed DNA Polymerase Activity Targets
12.1.12 DNA-Methyltransferase Activity Targets
12.1.13 Extracellular Matrix Structural Constituent Targets
12.1.14 G-Protein Coupled Receptor Activity Targets
12.1.15 Growth Factor Activity Targets
12.1.16 Hydrolase Activity Targets
12.1.17 Kinase Regulator Activity Targets
12.1.18 Lipase Activity Targets
12.1.19 MHC Class I Receptor Activity Targets
12.1.20 Molecular Function Unknown Targets
12.1.21 Motor Activity Targets
12.1.22 Oxidoreductase Activity Targets
12.1.23 Protein Binding Targets
12.1.24 Protein Serine/Threonine Kinase Activity Targets
12.1.25 Protein Threonine/Tyrosine Kinase Activity Targets
12.1.26 Protein Tyrosine Phosphatase Activity Targets
12.1.27 Receptor activity
12.1.28 Receptor Binding Targets
12.1.29 Receptor Signaling Complex Scaffold Activity Targets
12.1.30 Transcription Factor Activity Targets
12.1.31 Transcription Regulator Activity Targets
12.1.32 Transferase Activity Targets
12.1.33 Translation Regulator Activity Targets
12.1.34 Transmembrane Receptor Activity Targets
12.1.35 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
12.1.36 Transporter Activity Targets

13 The Drug-Target Interactome

14 The Progression and Maturity of Melanoma Targets
14.1 Target Profiles of Melanoma Drugs in Pre-Registration to Marketed
14.2 New and Unique Melanoma Targets in Phase III Clinical Development
14.3 New and Unique Melanoma Targets in Phase II Clinical Development
14.4 New and Unique Melanoma Targets in Phase I Clinical Development
14.5 New and Unique Melanoma Targets in Preclinical Development
14.6 Development Profiles of All Melanoma Target Combinations

15 Targets by R&D Approach in Melanoma
15.1 Small Molecules
15.1.1 Background
15.1.2 Targets in Melanoma
15.2 Peptide/Protein Drugs
15.2.1 Background
15.2.2 Targets in Melanoma
15.3 Monoclonal Antibodies and Antibody-Like Structures
15.3.1 Background
15.3.2 Targets in Melanoma
15.4 Nucleic Acid Therapies
15.4.1 Background
15.4.2 Targets in Melanoma
15.5 Gene Therapy
15.5.1 Background
15.5.2 Targets in Melanoma
15.6 Drug Delivery and Nanotechnology
15.6.1 Background
15.6.2 Targets in Melanoma

16 Melanoma Targets by Companies
16.1 Australia
16.2 Canada
16.3 Denmark
16.4 France
16.5 Germany
16.6 Israel
16.7 Italy
16.8 Japan
16.9 Norway
16.10 South Korea
16.11 Spain
16.12 Sweden
16.13 Switzerland
16.14 United Kingdom
16.15 USA

17 Disclaimer

18 Drug Index
19 Company Index

4.1 List of Figures
Figure 1: Distribution of Compound Types among Melanoma Drugs
Figure 2: Primary Sub-cellular Localization of Drug Targets
Figure 3: Visualization of Target-Target Interactions Among Melanoma Drug Targets
Figure 4: The Drug-Protein Interactome of Melanoma Drugs
Figure 6: Head-to-Head Targeting Interactome of Melanoma Drugs

4.2 List of Tables
Table 1: Compound Strategies based on Sub-Cellular Localization of Melanoma Drug Targets
Table 2: Drug Targets of Melanoma Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census
Table 3: Expression Levels of Identified Drug Targets in Malignant Melanoma Tissue
Table 4: Pathway Summary
Table 5: Drug Targets without any Identified Assigned Pathways
Table 6: Pathway Profile According to BioCarta of Melanoma Drug Targets
Table 7: Pathway Profile According to KEGG of Melanoma Drug Targets
Table 8: Pathway Profile According to NetPath of Melanoma Drug Targets
Table 9: Target-Target Interactions among Melanoma Drug Targets
Table 10: Identity of Melanoma Drug Targets with Available Biological Structures
Table 11: Overview of Drug Target Profile Themes
Table 12: Drug-Protein Interactome Clusters
Table 13: Fall Out in Terms of the Total Number of Drug Target Mixes, Drugs, and the Presence of New Drug Target Mixes by Developmental Stage.
Table 14: Top 5 Competitive Melanoma Targets
Table 15: Target Profiles of Melanoma Drugs in Pre-Registration to Marketed
Table 16: New and Unique Melanoma Targets in Phase III Clinical Development
Table 17: New and Unique Melanoma Targets in Phase II Clinical Development
Table 18 New and Unique Melanoma Targets in Phase I Clinical Development
Table 19: New and Unique Melanoma Targets in Preclinical Development
Table 20: The Progression, Maturity and Competitive Comparison of Melanoma Drug Targets in Development
Table 21: Number of Melanoma Drug Target Mixes Reported by Line of Therapy
Table 22: Number of Head-to-head Competing Small Molecule Drugs for the Treatment of Melanoma by Drug Target
Table 23: Drug Targets of Small Molecule Drugs in Melanoma
Table 24: Mechanistic Relationship between Small Molecule Drugs in Melanoma
Table 25: Drug Targets of Peptide Based Drugs in Melanoma
Table 26: Drug Targets of Protein Based Drugs in Melanoma
Table 27: Drug Targets of Monoclonal Antibodies and Antibody-Like Drugs in Melanoma
Table 28: Drug Targets of Nucleic Acid Therapies in Melanoma
Table 29: Vectors in Gene Therapy
Table 30: Drug Targets of Gene Therapies in Melanoma
Table 31: Drug Targets with New Drug Delivery Strategies in Melanoma
Table 32: Melanoma Drugs with Drug Target Mix and Developmental Stage by Companies in Australia
Table 33: Melanoma Drugs with Drug Target Mix and Developmental Stage by Companies in Canada
Table 34: Melanoma Drugs with Drug Target Mix and Developmental Stage by Companies in Denmark
Table 35: Melanoma Drugs with Drug Target Mix and Developmental Stage by Companies in France
Table 36: Melanoma Drugs with Drug Target Mix and Developmental Stage by Companies in Germany
Table 37: Melanoma Drugs with Drug Target Mix and Developmental Stage by Companies in Israel
Table 38: Melanoma Drugs with Drug Target Mix and Developmental Stage by Companies in Italy
Table 39: Melanoma Drugs with Drug Target Mix and Developmental Stage by Companies in Japan
Table 40: Melanoma Drugs with Drug Target Mix and Developmental Stage by Companies in Norway
Table 41: Melanoma Drugs with Drug Target Mix and Developmental Stage by Companies in South Korea
Table 42: Melanoma Drugs with Drug Target Mix and Developmental Stage by Companies in Spain
Table 43: Melanoma Drugs with Drug Target Mix and Developmental Projects by Companies in Sweden
Table 44: Melanoma Drugs with Drug Target Mix and Developmental Stage by Companies in Switzerland
Table 45: Melanoma Drugs with Drug Target Mix and Developmental Stage by Companies in United Kingdom
Table 46: Melanoma Drugs with Drug Target Mix and Developmental Stage by Companies in USA

This report covers in-depth the following investigators:
Abbott
Abiogen
Abraxis BioScience
Actelion
Adherex
Advanced Life Sciences
Advaxis
Aeterna Zentaris
Ambit Biosciences
Antisense Pharma
Antisoma
Aphios
ARIUS Research
ArQule
Array BioPharma
Astellas
AstraZeneca
Attenuon
Bayer
Biogen Idec
Bio-Medisinsk Innovasjon
BioNumerik
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb
Cell Genesys
CJ Corp
Clavis Pharma
Cosmo Pharmaceuticals
CSL
CuraGen
CytImmune Sciences
Cytokinetics
Deciphera Pharmaceuticals
DNAVEC
Dong-A
Eisai
Eli Lilly
Enzon
EpiCept
Exelixis
Genentech
Genta
GenVec
Genzyme
GlaxoSmithKline
Hemispherx Biopharma
Hoffmann-La Roche
Ichor Medical Systems
Idera Pharmaceuticals
ImClone Systems
Immutep
Inotek
Inovio
Introgen Therapeutics
Ipsen
Jennerex Biotherapeutics
Johnson & Johnson
LG Life Sciences
MAT Biopharma
Medarex
MediGene
Merck KGaA
Mochida
MolMed
Mologen
Novartis
OSI Pharmaceuticals
Oxford BioMedica
PBL Therapeutics
PDL BioPharma
Pfizer
PharmaMar
Plexxikon
Progen
Reata Pharmaceuticals
Regulon
SciClone Pharmaceuticals
Seattle Genetics
Shire
Solbec Pharmaceuticals
SuperGen
Swedish Orphan
Takeda
Targa Therapeutics
Targepeutics
TopoTarget
Tracon Pharmaceuticals
Transgene
Vascular Biogenics
Vical
VioQuest
ViroTarg
York Pharma
ZymoGenetics
Includes a total of 125 melanoma drugs. Some examples are:
852A
ABI-007
AG-14699
aldesleukin
Allovectin-7
Ampligen
AP-12009
aplidine
APO-866
ARRY-886
ATN-224
axitinib
belinostat
BNP-1350
bortezomib
bosentan
CB-10-01
cilengitide
CNTO-95
CP-4055
CR-011-vcMMAE
decitabine
EMD-273063
epirubicin
GC-1008
gefitinib
GVAX
Hi-8 MEL
histamine dihydrochloride
IMC-1121b
ImmunoVEX tri-melan
indisulam
INGN-241
INO-1001
interferon
interleukin-21
ipilimumab
ispinesib mesylate
JX-594
kahalalide F
LipoVIL12
MAGE-3-TK cancer vaccine
MAGE-A3 vaccine
melanoma vaccine
MetXia
MS-275
oblimersen sodium
OncoVEX
PD-0325901
perifosine
PF-3512676
phosphomannopentaose sulfate
RTA-402
sargramostim
sorafenib tosylate
sunitinib malate
tanespimycin
thymalfasin
TNFerade
tremelimumab
volociximab
VQD-001
YM-15

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Currently Druggable in Melanoma: A Drug Target Competitive Analysis.
    To find out more about Currently Druggable in Melanoma: A Drug Target Competitive Analysis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Currently Druggable in Melanoma: A Drug Target Competitive Analysis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Competitive Outlook on Non-Antibody Based Cancer Vaccines
Research and development in the cancer vaccine field is dominated by its top 10 players, interestingly not including any of the big pharma companies per se. The recent Gardasil approval and GlaxoSmithKline’s acquisition of Corixa will certainly push the industry towards more acquisitions. With this in mind, this report makes an in-depth assessment of competitive landscape, tumor antigen technologies, immunostimulatory strategies, vaccine delivery technologies, and a progress analysis of six major cancer vaccine indications. Learn More


Cancer Vaccines: From First-in-Class to Best-in-Class?
In-depth pipeline analytics of cancer vaccine drugs showing you where the competition is, what is first-in-class and is first-in-class the best-in-class?, Indication expansion opportunities and much more Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Breast Cancer, Lung Cancer and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Lung Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More


Head and Neck Cancer Drug Pathway Analyzer
There are today at least 236 targeted molecular therapies known to affect more than 246 specific intracellular signaling pathways for the treatment of head and neck cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 211 drug targets that are included in this drug-pathway analyzing tool. No less than 199 of these have been recorded with mutations and 43 drug targets have mutations which have been causally implicated in cancer. Learn More